Share on StockTwits

Acura Pharmaceuticals (NASDAQ:ACUR) VP James F. Emigh purchased 15,000 shares of the company’s stock on the open market in a transaction dated Friday, May 16th. The stock was purchased at an average price of $1.21 per share, with a total value of $18,150.00. Following the acquisition, the vice president now directly owns 198,304 shares in the company, valued at approximately $239,948. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Acura Pharmaceuticals (NASDAQ:ACUR) traded up 0.82% on Monday, hitting $1.23. 52,011 shares of the company’s stock traded hands. Acura Pharmaceuticals has a one year low of $1.08 and a one year high of $2.59. The stock’s 50-day moving average is $1.32 and its 200-day moving average is $1.61. The company’s market cap is $60.1 million.

Acura Pharmaceuticals (NASDAQ:ACUR) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.08) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.05) by $0.03. On average, analysts predict that Acura Pharmaceuticals will post $-0.31 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on ACUR shares. Analysts at MLV & Co
cut their price target on shares of Acura Pharmaceuticals from $2.25 to $2.00 in a research note on Friday, May 9th.

Acura Pharmaceuticals, Inc, is a specialty pharmaceutical company engaged in the research, development and commercialization of products focused on addressing medication abuse and misuse, utilizing its Aversion and Impede Technologies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.